Vertex Pharmaceuticals Incorporated v. Lupin Limited et al
| Vertex Pharmaceuticals Incorporated |
| Lupin Limited and Lupin Pharmaceuticals, Inc. |
| 1:2023cv00581 |
| May 26, 2023 |
| US District Court for the District of Delaware |
| Richard G Andrews |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. ยง 271 Patent Infringement |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on July 18, 2023. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 10 REDACTED VERSION of #8 Letter, by Vertex Pharmaceuticals Incorporated. (Fahnestock, Derek) Modified on 7/19/2023 (nms). |
| REDACTION NOTICE: In accordance with section G of the Administrative Procedures Governing Filing and Service by Electronic Means, redacted versions of sealed documents shall be filed electronically within 7 days of the filing of the sealed document. The records of this case do not reflect the filing of a redacted version of DI #8 . (nms) |
Filing 9
ORAL ORDER: The request to consolidate (D.I. 7 in 23-cv-582-RGA; D.I. 7 in 23-cv-581-RGA; D.I. 190 in 20-cv-988-RGA-CJB; D.I. 7 in 23-cv-666-RGA) is GRANTED. These actions are consolidated for all purposes including trial, and all filings shall be made in C.A. No. 20-988-RGA-CJB ONLY. All requests to amend the scheduling order will be handled by Magistrate Judge Christopher J. Burke. Ordered by Judge Richard G. Andrews on 7/10/2023. Associated Cases: 1:20-cv-00988-RGA-CJB, 1:23-cv-00581-RGA, 1:23-cv-00582-RGA, 1:23-cv-00666-RGA(nms)
|
| Filing 8 [SEALED] Letter to The Honorable Richard G. Andrews, from Derek J. Fahnestock, regarding proposed consolidated scheduling order. (Fahnestock, Derek) Modified on 7/10/2023 (nms). |
| Filing 7 Joint Stipulation and [Proposed] Order to Consolidate and Amend Scheduling Order, by Vertex Pharmaceuticals Incorporated. (Fahnestock, Derek) Modified on 7/10/2023 (nms). |
| Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. Associated Cases: 1:23-cv-00581-RGA, 1:23-cv-00582-RGA, 1:23-cv-00583-RGA (rjb) |
| Filing 6 Summons Issued as to Lupin Pharmaceuticals, Inc. and Lupin Limited on 5/26/2023. (Attachments: #1 Summons Issued Lupin Limited)(jdb) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Vertex Pharmaceuticals Incorporated. (jdb) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,564,916 B2. (jdb) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: April 26, 2023. Date of Expiration of Patent: August 13, 2029. (jdb) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (jdb) |
| Filing 1 COMPLAINT against Lupin Limited and Lupin Pharmaceuticals, Inc. (Filing fee $ 402, receipt number ADEDC-4145756) - filed by Vertex Pharmaceuticals Incorporated. (Attachments: #1 Exhibit A, #2 Civil Cover Sheet)(jdb) Modified on 5/31/2023 (nms). |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
